On August 22, 2024, the Food and Drug Administration amended the emergency use authorization (EUA) of Pfizer-BioNTech COVID-19 Vaccine to include the 2024-2025 formula. The Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) includes a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. The Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) is authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19.
Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) is authorized for use as follows:
Individuals 6 months through 4 years of age:
- Unvaccinated individuals: Three doses of Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) are administered. The first two doses are administered three weeks apart. The third dose is administered at least 8 weeks after the second dose.
- Individuals who have received one previous dose of any Pfizer BioNTech COVID-19 Vaccine that is no longer authorized for use in the United States: Two doses of Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) are administered. The first dose of Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) is administered three weeks after receipt of the previous dose and the second dose is administered at least 8 weeks later.
- Individuals who have received two or more previous doses of any Pfizer BioNTech COVID-19 Vaccine that is no longer authorized for use in the United States: A single dose of Pfizer-BioNTech COVID 19 Vaccine (2024-2025 Formula) is administered at least 8 weeks after receipt of the last previous dose.
Individuals 5 years through 11 years of age, regardless of vaccination status:
- A single dose of Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula). If previously vaccinated with any COVID-19 vaccine that is no longer authorized for use in the United States, administer at least 2 months after receipt of the last previous dose of any COVID-19 vaccine.
Immunocompromised individuals 6 months through 11 years of age:
- Complete at least a three-dose series with a COVID-19 vaccine with an age appropriate dose and dosing schedule. At least one dose should be with a COVID-19 vaccine (2024-2025 Formula).
Pfizer-BioNTech COVID-19 Fact Sheets and Materials
| Material | Audience | Last Updated |
|---|---|---|
| Fact Sheet | Recipient and Caregiver | August 22, 2024 |
| Fact Sheet | Healthcare Provider | August 22, 2024 |
Pfizer-BioNTech Regulatory Information (Emergency Use Authorization)
Federal Register Notices
Translations of the Fact Sheet for Recipients and Caregivers
-
Content current as of:
10/15/2024
-
Regulated Product(s)
Health Topic(s)
Clinical :: Oncology :: Nuclear :: Geriatric :: Regulatory :: Technology :: Consulting
"My passion is helping businesses, small and large, perform at their best." - Felicia Udoji-Eddings, Pharm.D.
Dr. Felicia Udoji-Eddings is the Founder and CEO of The Health Pals Company, a vertically integrated Healthcare System. As an experienced Clinical Pharmacy Leader, Pharmacy Consultant, Healthcare Executive, and Licensed Pharmacy Practitioner with deep backgrounds in Information Technology (IT), Scientific Research, and Business Management. Dr. Udoji-Eddings has a strong track record of exceptional performance in different business environments. A skilled Business Strategist, Dr. Udoji-Eddings has tackled complex problems and helped several organizations refocus their strategy in tough economic times. As a highly motivated and proactive individual, Felicia enjoys working with teams, in various capacities, to facilitate positive outcomes.
Our Pill Pass® Drug List is only $6.99 or less and Shipping is FREE!
